此 乃 要 件 請 即 處 理 國藥科技股份有限公司 （於開曼群島註冊成立之有限公司） （股份代號：8156） 發行股份及購回股份之 一般授權、 重選退任董事、 選舉董事之建議 及 股東週年大會通告 本公司謹訂於二零二五年十二月十九日（星期五）上午十一時正假座香港中環都爹利街11號律敦治中心律敦 治大廈13樓1302–3室舉行股東週年大會（「股東週年大會」），大會通告載於本通函第17至21頁內。本通函隨 附股東週年大會適用之代表委任表格。 無論 閣下能否出席股東週年大會，務請儘快將隨附之代表委任表格按其印備之指示填妥，並在任何情況 下不遲於股東週年大會或其任何續會指定舉行時間48小時前交回本公司之香港股份登記及過戶分處卓佳標 準有限公司，地址為香港夏愨道16號遠東金融中心17樓。填妥及交回代表委任表格後， 閣下仍可親身出 席股東週年大會或其任何續會並於會上投票，於該情況下，代表委任表格將被視作已撤銷論。 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之持牌證券交易商、銀行經理、律 師、專業會計師或其他專業顧問。 閣下如已將名下之國藥科技股份有限公司（「本公司」）股份全部售出或轉讓，應立即將本通函 ...

茲通告國藥科技股份有限公司（「本公司」）謹訂於二零二五年十二月十九日（星期五） 上午十一時正假座香港中環都爹利街11號律敦治中心律敦治大廈13樓1302–3室舉行 股東週年大會（「股東週年大會」），藉以處理下列事項： 普通決議案 – 1 – 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 （於開曼群島註冊成立之有限公司） （股份代號：8156） 股東週年大會通告 1. 省覽本公司截至二零二五年六月三十日止年度之經審核綜合財務報表、本公司 董事會報告及獨立核數師報告； 2. (a) 重選趙善能先生為執行董事； (b) 重選向碧倫先生為獨立非執行董事； (c) 選舉刁志強先生為獨立非執行董事； (d) 選舉余秉明先生為獨立非執行董事；及 (e) 授權董事會（「董事會」或「董事」）釐訂董事之酬金； 3. 續聘蘇亞文舜會計師事務所有限公司為本公司核數師並授權董事會釐定彼等酬 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | ...

Core Points - The company announced the resignation of Ms. Huang Ziling as the company secretary, effective from October 23, 2025 [1] - Mr. Guo Zuyi has been appointed as the new company secretary, also effective from October 23, 2025 [1]

Group 1 - The company announced the resignation of Ms. Huang Ziling as the company secretary, effective from October 23, 2025 [1] - Mr. Guo Zuyi has been appointed as the new company secretary, also effective from October 23, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號: 8156) 更換公司秘書 國藥科技股份有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此宣佈 黃子玲女士（「黃女士」）已辭任本公司公司秘書（「公司秘書」），自二零二五年十 月二十三日起生效。黃女士已確認其與董事會概無意見分歧，亦無其他與其辭任有關的 事項需要通知香港聯合交易所有限公司或本公司股東。 董事會進一步宣佈郭祖貽先生（「郭先生」）已獲委任為公司秘書，自二零二五年十月 二十三日起生效。 郭先生為香港會計師公會及澳洲會計師公會會員。郭先生於香港及澳洲擁有逾20年會 計、核數、財務及公司秘書領域的經驗。彼於澳洲悉尼科技大學取得會計及財務碩士學 位，並於澳洲麥覺理大學取得工商管理學士學位。 董事會謹藉此機會對黃女士在任期間對本公司所作出之寶貴貢獻致以讚賞及謝意 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | ...

Group 1 - The core viewpoint of the article highlights that China National Pharmaceutical Group Technology Co., Ltd. (国药科技股份) reported a significant improvement in its financial performance for the year ending June 30, 2025, with revenue reaching approximately HKD 61.3 million, representing a year-on-year increase of about 48% [1] - The company reported a loss attributable to shareholders of approximately HKD 0.9 million, which is a substantial reduction of about 95% compared to the previous year [1] - The increase in revenue is primarily attributed to the rising demand in the health products market and improved operational efficiency in supply chain services, underscoring the effectiveness of the company's strategic focus on these core business areas [1] Group 2 - The board of directors noted that the significant improvement in the group's financial performance this year is mainly due to several net impacts, including a gross profit increase of approximately HKD 9.2 million or 184% year-on-year due to business improvements [1] - The company has strengthened cost control over administrative and operational expenses [1] - The company recorded capitalized loan income of approximately HKD 3.9 million this year, which contributed to a reduction in financing costs due to the capitalized loans [1]

Core Viewpoint - China National Pharmaceutical Group Technology Co., Ltd. (国药科技股份) reported a significant improvement in its financial performance for the year ending June 30, 2025, with a revenue increase of approximately 48% year-on-year, reaching about HKD 61.3 million, and a substantial reduction in net loss by about 95% to approximately HKD 0.9 million [1] Financial Performance - Revenue for the year was approximately HKD 61.3 million, representing a year-on-year increase of about 48% [1] - The loss attributable to owners was approximately HKD 0.9 million, a significant decrease of about 95% compared to the previous year [1] - Earnings per share reflected a loss of HKD 0.0019 [1] Factors Contributing to Performance - The revenue growth was primarily driven by increased demand in the health products market and improved operational efficiency in supply chain services, highlighting the effectiveness of the company's strategic focus on these core business areas [1] - The board noted several key factors contributing to the improved financial performance, including: - A year-on-year gross profit increase of approximately HKD 9.2 million or 184% due to business improvements [1] - Enhanced cost control over administrative and operational expenses [1] - Capitalized loan income of approximately HKD 3.9 million for the year [1] - Reduced financing costs due to loan capitalization during the year [1]

Financial Performance - For the fiscal year ending June 30, 2025, the company experienced significant revenue growth driven by increased demand for health products, improved supply chain efficiency, and optimized service processes[8]. - The company recorded revenue of approximately HKD 61,300,000 for the year, an increase of about 48% compared to HKD 41,200,000 in the same period of 2024[18]. - Gross profit for the year was approximately HKD 14,200,000, representing an increase of about 184% from HKD 5,000,000 in the previous year, driven by higher gross margins in health product supply chain services[18]. - The company reported a loss attributable to shareholders of approximately HKD 900,000, significantly reduced by about 95% from a loss of HKD 19,700,000 in the previous year[18]. - The supply chain services segment generated revenue of approximately HKD 61,300,000, with a gross margin of about 23%, compared to a gross margin of 12% in the previous year[21]. Strategic Focus and Operations - The company has strategically paused investments in the "Internet+" solutions and personal protective equipment sectors, focusing resources on high-growth areas such as AI applications and pharmaceutical sales[8]. - The company aims to strengthen its core competitiveness by reallocating resources towards high-potential areas within the health industry and supply chain services[12]. - The company plans to focus on the health industry and supply chain services, with an emphasis on AI applications in healthcare, life sciences, and data science[14]. - The company is committed to continuing its digital transformation and AI-driven operations to achieve long-term value growth[11]. - The integration of data-driven market insights has effectively assisted clients in seizing business opportunities, contributing to the company's growth[10]. Financial Management and Capital Structure - The company will continue to optimize its capital structure and strictly control financial risks to support future business expansion[17]. - The group completed a capital restructuring and loan capitalization, reducing debt burden by approximately HKD 193,000,000, which strengthens the equity base for future growth[31]. - Current liabilities significantly decreased to approximately HKD 68,400,000 from HKD 249,400,000 in 2024, reflecting successful debt management and balance sheet optimization[26]. - The capital debt ratio improved to approximately 9% as of June 30, 2025, compared to 162% in 2024, demonstrating enhanced financial stability[26]. - The group remains focused on maintaining sufficient liquidity to support ongoing operations and strategic initiatives while ensuring prudent financial management[27]. Corporate Governance - The board is committed to maintaining high levels of corporate governance and effective accountability systems to protect shareholder interests and promote business growth[42]. - The company has adopted the GEM Listing Rules Appendix C1 Corporate Governance Code, with some deviations noted, particularly regarding the separation of the roles of Chairman and CEO[43]. - The roles of Chairman and CEO are currently held by executive directors, which the board believes benefits the company's business prospects and management[47]. - The company will periodically review and update its corporate governance practices to comply with GEM Listing Rules as deemed appropriate[45]. - The company has established mechanisms to ensure independent insights and input for the board, including annual reviews of board structure and diversity policies[53]. Risk Management - The company faces risks related to fluctuations in market demand for health products and pharmaceuticals, which are influenced by consumer preferences and macroeconomic trends[94]. - The company has implemented AI demand forecasting and dynamic inventory mechanisms to enhance operational efficiency and cost control[95]. - The board conducts an annual review of the effectiveness of the risk management and internal control systems, covering financial, operational, and compliance monitoring[70]. - The company has established a comprehensive risk management and internal control system to ensure the reliability of financial information and prevent fraud[67]. - The company continues to seek alternative financing and bank loans to settle existing financial obligations and fund future operations and capital expenditures[68]. Environmental, Social, and Governance (ESG) Initiatives - The company has implemented energy-saving measures to reduce greenhouse gas emissions, which are the primary source of its carbon footprint[168]. - The company has adopted responsible waste management policies to minimize waste generation and ensure proper disposal[168]. - The company has committed to reducing greenhouse gas emissions and waste generation as part of its environmental, social, and governance (ESG) initiatives[185]. - The company has not produced any packaging materials for finished products this year, maintaining a density of 0 tons per business unit[183]. - The company has set a target to keep air pollutants and greenhouse gas emissions at or below the levels recorded as of June 30, 2020[175]. Employee Management and Development - The total number of employees as of June 30, 2025, is 33, with 19 males and 13 females[190]. - Employee turnover rate for males is 5.13% as of June 30, 2025, down from 30.30% in the previous year[191]. - The company provides various healthcare plans and has implemented COVID-19 preventive measures for employee safety[195]. - The company encourages employee development through external training and continuous education opportunities[196]. - Percentage of trained employees is 78.95% for males and 100% for females as of June 30, 2025[198].